Skip to main content
Insights into Imaging
Fig. 3 | Insights into Imaging

Fig. 3

From: Cost-effectiveness of the implementation of [68Ga]Ga-PSMA-11 PET/CT at initial prostate cancer staging

Fig. 3

PrSA bootstrap analysis of 10,000 samples on cost-effectiveness of [68Ga]Ga-PSMA-11 PET/CT versus standard of care, plotted on the cost-effectiveness plane (incremental utility versus incremental cost). The triangle reflects the deterministic result. Results are mainly in the south-west quadrant, indicating a reduction in quality of life and cost-savings. PET/CT Positron emission tomography/computed tomography, PrSA probabilistic sensitivity analysis PSMA prostate specific membrane antigen, QALY quality-adjusted life years

Back to article page